NXGL

NexGel, Inc. (NXGL) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2026. NexGel, Inc. manufactures hydrogel products for wound care, medical diagnostics, and cosmetics. The company operates through two primary segments: the NexGel segment (manufacturing and branded consumer products) and the CGN Joint Venture (converting and packaging). A significant strategic development in this period was the acquisition of an exclusive license and assets from Celularity, Inc., creating a new "BioNx" line of business focused on regenerative biomaterials.

Key Financial Metrics (Six Months Ended June 30, 2026)

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 11.4% year-over-year (YoY) to $6.336 million, driven primarily by $814,000 in new Biomaterial product sales from the Celularity acquisition. This was partially offset by a $289,000 decline in Consumer Branded Products.
• Margin Compression: Gross margin decreased from 43.0% in the prior year to 34.2%. This decline is attributed to lower initial margins on new Biomaterial products, increased inventory write-offs, and higher freight and royalty costs.
• Expense Surge: Selling, General, and Administrative (SG&A) expenses rose 45.5% YoY to $5.613 million. Key drivers include $756,000 in amortization of the Celularity license intangible asset and $657,000 in costs to establish the BioNx Surgical division.
• Balance Sheet Expansion: Total assets more than doubled from $10.5 million to $26.4 million, largely due to the recognition of $13.5 million in intangible assets from the Celularity deal. Conversely, current liabilities surged to $14.4 million, resulting in negative working capital of $8.3 million.
• Debt Financing: The company raised approximately $8.6 million in convertible notes in April and May 2026 to fund the Celularity transaction, significantly increasing leverage and creating a substantial derivative liability.

Outlook, Risks, and Management Commentary

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Unrestricted cash is only $0.5 million, and the company incurred a net loss of $4.5 million for the six-month period. Continued operations depend on raising additional capital and the success of the BioNx commercialization.
• Debt Risks: The company holds $14.7 million in convertible notes with 10% interest (18% on default) and complex conversion features (full-ratchet anti-dilution, price resets). Management noted potential events of default regarding registration statement filings and authorized share reserves, though no acceleration has been declared.
• Contingent Liabilities: The Celularity agreement includes up to $20 million in contingent milestone payments. Additionally, the company is facing an arbitration claim from Bezalel Partners, LLC seeking over $1.75 million in finder's fees.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and journal entry approvals.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for the next capital raise given the $0.5 million unrestricted cash balance and negative operating cash flow.
• Debt Covenants: Confirm the status of the potential defaults regarding the registration statement (Form S-1) and the sufficiency of authorized shares for note conversions.
• BioNx Commercialization: Assess the actual sales trajectory of the new Biomaterial products versus the high amortization costs ($756k in Q2) to determine path to profitability.
• Derivative Liability Volatility: Monitor the fair value of the $8.7 million derivative liability, which fluctuates with stock price and could significantly impact future earnings.
• Legal Proceedings: Track the outcome of the Bezalel Partners arbitration and any potential impact on cash reserves.